Biorxiv: the first in vitro synthesis of a new coronavirus, only a week!

February 26, 2020 / BIOON / -- reverse genetics is an indispensable tool, which has completely changed our understanding of viral pathogenesis and vaccine development Large RNA virus genomes, such as coronavirus genomes, are cumbersome to clone and operate in E.coli hosts because of their large size and sometimes instability Therefore, to provide another rapid and applicable reverse genetics platform for RNA virus will help researchers to speed up relevant research Recently, researchers from the University of Bern, Switzerland and the Institute of virus and immunology and other institutions cooperated in the preprint website biorixv to show a new research without peer review, which shows a synthetic genomics based on yeast The complete function of the platform is used for genetic reconstruction of various RNA viruses including members of coronaviridae, Flaviviridae and Paramyxoviridae Picture source: the subgenomic fragment of bioRxiv virus is produced by using virus isolate, clone virus DNA, clinical sample or synthetic DNA, and is reassembled in Saccharomyces cerevisiae by using transformation related recombination (TAR) clone step by step to maintain the genome as yeast artificial chromosome (YAC) T7-rna polymerases are used to produce infectious RNA, which is then used to save living viruses Based on this platform, researchers have been able to engineer and regenerate the chemical synthetic clone of sars-cov-24 within one week after receiving the synthetic DNA fragment The technological advances described by the researchers here enable us to respond quickly to emerging viruses because they can generate and describe the functions of evolving RNA virus variants in real time during an outbreak Reference: tran thi nhu Thao et al Rapid reconstruction of sars-cov-2 using a synthetic genomics platform Biorixv Doi: https://doi.org/10.1101/2020.02.21.959817